This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~Use of~~A method for the treatment of a disease in which inhibition, regulation and/or modulation of kinase signal transduction plays a role, comprising administering, to a host in need thereof, an effective amount of one or more ~~of the~~ compounds of ~~the~~ formula I



in which

Ar^1 denotes phenyl, naphthyl, biphenyl or Het, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by R^1,

Ar^2 denotes phenyl, naphthyl, biphenyl or Het, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by R^2,

Y denotes O, S, $CH\text{-}NO_2$, $C(CN)_2$ or $N\text{-}R^4$,

Z denotes -O-, -S-, $-CH_2-(CH_2)_n-$, $-(CH_2)_n-CHA-$, $-CHA-(CH_2)_n-$, $-C(=O)-$, $-CH(OH)-$, $-(CHA)_nO-$, $-(CH_2)_nO-$, $-O(CHA)_n-$, $-O(CH_2)_n-$, $-(CH_2)_nS-$, $-S(CH_2)_n-$, $-(CH_2)_nNH-$, $-NH(CH_2)_n-$, $-(CH_2)_nNA-$, $-NA(CH_2)_n-$, -CHHal- or $-C(Hal)_2-$,

Het denotes a mono- or bicyclic aromatic heterocycle having 1 to 4 N, O and/or S atoms,

R^1, R^2, independently of one another, denote A, Ar', OR^3, SR^3, OAr', SAr', $N(R^3)_2$, NHAr', Hal, NO_2, CN, $(CH_2)_nCOOR^3$, $(CH_2)_nCON(R^3)_n$, COR^3, $S(O)_mA$, $S(O)_mAr'$, NHCOA, NHCOAr', $NHSO_mA$, $NHSO_mAr'$, $SO_mN(R^3)_2$, $-O-(CH_2)_n-N(R^3)_2$, $O(CH_2)_nNHR^3$,

$O(CH_2)_nNA_2$, $O(CH_2)_nC(CH_3)_2(CH_2)_nN(R^3)_2$,
$NH(CH_2)_n(CH_3)_2(CH_2)_nN(R^3)_2$, $O(CH_2)_nN(R^3)SO_mA$,
$O(CH_2)_nN(R^3)SO_mN(R^3)A$, $O(CH_2)_nN(R^3)SO_mAr'$, $(CH_2)_nN(R^3)SO_mA$,
$(CH_2)_nN(R^3)SO_mN(R^3)A$, $(CH_2)_nN(R^3)SO_mAr'$, $O(CH_2)_nSO_mA$,
$O(CH_2)_nSO_mN(R^3)A$, $O(CH_2)_nSO_mAr'$, $(CH_2)_nSO_mA$,
$(CH_2)_nSO_mN(R^3)A$, $(CH_2)_nSO_mAr'$, -NH-$(CH_2)_n$-NH_2, -NH-$(CH_2)_n$-NHA, -NH-$(CH_2)_n$-NA_2, -NA-$(CH_2)_n$-NH_2, -NA-$(CH_2)_n$-NHA, -NA-$(CH_2)_n$-NA_2, -O-$(CH_2)_n$-Het^1 or Het^1,

R^3 denotes H, A or $(CH_2)_nAr'$,

R^4 denotes H, CN, OH, A, $(CH_2)_mAr'$, COR^3, COAr', $S(O)_mA$ or $S(O)_mAr'$,

Ar' denotes phenyl which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by A, Ph, OH, OA, SH, SA, OPh, SPh, NH_2, NHA, NA_2, NHPh, Hal, NO_2, CN, $(CH_2)_nCOOH$, $(CH_2)_nCOOA$, $(CH_2)_nCONH_2$, $(CH_2)_nCONHA$, CHO, COA, $S(O)_mA$, $S(O)_mPh$, NHCOA, NHCOPh, $NHSO_2A$, $NHSO_2Ph$ or SO_2NH_2,

Ph denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A, Hal, CN, COOR, COOH, NH_2, NO_2, OH or OA,

Het^1 denotes a monocyclic saturated heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, CN, $(CH_2)_nOH$, $(CH_2)_nHal$, NH_2, =NH, =N-OH, =N-OA and/or carbonyl oxygen (=O),

A denotes alkyl having 1 to 10 C atoms, where 1-7 H atoms may also be replaced by F and/or chlorine,

Hal denotes F, Cl, Br or I,

n denotes 0, 1, 2, 3, 4 or 5,

m denotes 0, 1 or 2,

~~and~~or pharmaceutically usable ~~derivatives~~, solvates, salts ~~and~~or stereoisomers thereof, including mixtures thereof in all ratios~~, for the preparation of a medicament for the prophylaxis and/or treatment of diseases in which the inhibition, regulation and/or modulation of kinase signal transduction plays a role~~.

2. (Currently Amended) ~~Use~~A method according to Claim 1, ~~characterised in that~~wherein the disease is ~~(are)~~ caused, mediated and/or propagated by thyrosine and/or Raf kinase(s).

3. (Currently Amended) ~~Use~~A method according to Claim 2, ~~characterised in that~~wherein the disease is caused, mediated and/or propagated by A-Raf, B-Raf and/or Raf-1 kinase.

4. (Currently Amended) ~~Use~~A method according to Claim 1, ~~characterised in that~~wherein the disease is a hyperproliferative disease.

5. (Currently Amended) ~~Use~~A method according to Claim 4, ~~characterised in that~~wherein the disease is a cancer-like disease.

6. (Currently Amended) ~~Use~~A method according to Claim 5, ~~characterised in that~~wherein the disease is brain cancer, lung cancer, squamous epithelium cancer, bladder cancer, stomach cancer, pancreatic cancer, liver cancer, kidney cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, thyroid cancer, lymphoma, chronic leukaemia or acute leukaemia.

7. (Currently Amended) ~~Use~~A method according to Claim 4, ~~characterised in that~~wherein the disease is not cancer-like.

8. (Currently Amended) ~~Use~~A method according to Claim 7, ~~characterised in that~~wherein the disease is psoriasis, endometriosis, scarring or benign prostate hyperplasia.

9. (Currently Amended) ~~Use~~A method according to Claim 1, ~~characterised in that~~wherein the disease is an inflammation, arthritis, Helicobacter pylori infection, influenza A, an immunological disease, an autoimmune disease or an immunodeficiency disease.

10. (Currently Amended) ~~Use~~A method according to Claim 1, ~~characterised in that~~comprising administering a compound of the formula I ~~is employed~~ in which

Z denotes $-CH_2-(CH_2)_n-$, $-(CH_2)_n-CHA$, -CHA-O- or -O-,

~~and~~a pharmaceutically usable ~~derivatives~~, solvates, salts ~~and~~or stereoisomers thereof, including mixtures thereof in all ratios.

11. (Currently Amended) Compounds ~~general~~of formula VI



VI

in which

Ar^1 denotes phenyl which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by R^1,

Ar^2 denotes phenyl or Het, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by R^2,

Y denotes O,

Z denotes -O-, $-CH_2-(CH_2)_n-$, $-(CH_2)_n-CHA-$, $-CHA-(CH_2)_n-$, $-C(=O)-$,

-CH(OH)-, -CH(OA)-, -$(CH_2)_n$O-, -O$(CH_2)_n$-, -$(CH_2)_n$NH- or -NH$(CH_2)_n$-,

Het	denotes a mono- or bicyclic aromatic heterocycle having 1 to 4 N, O and/or S atoms,
R^1, R^2,	independently of one another, denote A, OR^3, Hal, NO_2, CN, $S(O)_mA$, $O(CH_2)_nNA_2$ or Het^1,
R^3	denotes H or A,
Het^1	denotes a monocyclic saturated heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, CN, $(CH_2)_n$OH, $(CH_2)_n$Hal, NH_2, =NH, =N-OH, =N-OA and/or carbonyl oxygen (=O),
A	denotes alkyl having 1 to 10 C atoms, where 1-7 H atoms may also be replaced by F and/or chlorine,
Hal	denotes F, Cl, Br or I,
n	denotes 0, 1, or 2,
m	denotes 0, 1 or 2,

~~and~~or pharmaceutically usable ~~derivatives,~~ solvates, salts ~~and~~or stereoisomers thereof, including mixtures thereof in all ratios.

12. (Currently Amended) Compounds of ~~the~~ formula I according to Claim ~~1~~11, ~~characterised in that these have~~of the following structures:

1-(2-methoxy-5-trifluoromethylphenyl)-3-(5-pyridin-4-ylmethyl-1,3,4-thiadiazol-2-yl)urea,

1-(5-chloro-2-methoxy-4-methylphenyl)-3-[5-(3,4-dimethoxybenzyl)-1,3,4-thiadiazol-2-yl]urea,

1-[5-(3,4-dimethoxybenzyl)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoro-methoxyphenyl)urea,

1-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoromethane-sulfonylphenyl)urea,

1-[5-(3,4-dimethoxybenzyl)-1,3,4-thiadiazol-2-yl]-3-(2-methoxy-5-trifluoromethylphenyl)urea,

1-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-3-p-tolylurea,

1-(2-methoxy-5-methylphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-urea,

1-(3-chloro-4-methylphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-urea,

1-(5-chloro-2-methylphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-urea,

1-(3-chloro-2-methylphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-urea,

1-(5-chloro-2-methoxyphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-urea,

1-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoromethylphenyl)urea,

1-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-3-(4-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxybenzyl)-1,3,4-thiadiazol-2-yl]-3-(2-methoxyphenyl)-urea,

1-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-3-(4-trifluoromethoxyphenyl)-urea,

1-(4-fluoro-3-trifluoromethylphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-(4-chloro-3-trifluoromethylphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-[5-(2,3-dimethoxybenzyl)-1,3,4-thiadiazol-2-yl]-3-(4-trifluoro-methoxyphenyl)urea,

1-[5-(2,3-dimethoxybenzyl)-1,3,4-thiadiazol-2-yl]-3-(2-trifluoro-methoxyphenyl)urea,

1-(5-chloro-2,4-dimethoxyphenyl)-3-[5-(3,4-dimethoxybenzyl)-1,3,4-thiadiazol-2-yl]urea,

1-(2,4-dimethoxyphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-(3-chloro-4-methoxyphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-urea,

1-[2-(2-dimethylaminoethoxy)-5-trifluoromethylphenyl]-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-[4-chloro-5-methyl-2-(piperidin-4-yloxy)phenyl]-3-[5-(3,4-di-methoxybenzyl)-1,3,4-thiadiazol-2-yl]urea,

1-(2-methoxy-5-trifluoromethylphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-(5-chloro-2-methoxy-4-methylphenyl)-3-(5-pyridin-4-ylmethyl-1,3,4-thiadiazol-2-yl)urea,

1-(5-pyridin-4-ylmethyl-1,3,4-thiadiazol-2-yl)-3-(3-trifluorometh-oxyphenyl)urea,

1-(5-chloro-2-methoxy-4-methylphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoromethoxyphenyl)-urea,

1-(2-methoxy-5-trifluoromethylphenyl)-3-[5-(1-phenylpropyl)-1,3,4-thiadiazol-2-yl]urea,

1-(5-chloro-2-methoxy-4-methylphenyl)-3-[5-(4-chlorophenoxymethyl)-1,3,4-thiadiazol-2-yl]urea,

1-[5-(4-chlorophenoxymethyl)-1,3,4-thiadiazol-2-yl]-3-(3-tri-fluoromethoxyphenyl)urea,

1-[4-chloro-2-(2-dimethylaminoethoxy)-5-methylphenyl]-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-[4-chloro-2-(2-dimethylaminoethoxy)-5-methylphenyl]-3-[5-(3,4-dimethoxybenzyl)-1,3,4-thiadiazol-2-yl]urea,

1-[5-(3,4-dimethoxybenzyl)-1,3,4-thiadiazol-2-yl]-3-[2-(2-dimethyl-aminoethoxy)-5-trifluoromethylphenyl]urea,

1-(2-methoxy-5-methylphenyl)-3-[5-(1-phenylpropyl)-1,3,4-thiadiazol-2-yl]-urea,

1-(2,5-dimethoxyphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-(2,5-dichlorophenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-[5-(hydroxyphenylmethyl)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoro-methylphenyl)urea,

1-(2-methoxy-5-methylphenyl)-3-[5-(2-methyl-1-phenylpropyl)-1,3,4-thiadiazol-2-yl]urea,

1-(2-fluoro-5-trifluoromethylphenyl)-3-(5-pyridin-4-ylmethyl-1,3,4-thiadiazol-2-yl)urea,

1-(4-fluoro-3-trifluoromethylphenyl)-3-(5-pyridin-4-ylmethyl-1,3,4-thiadiazol-2-yl)urea,

1-[5-(3,4-dimethoxybenzoyl)-1,3,4-thiadiazol-2-yl]-3-m-tolylurea,

1-{5-[2-(3,4-dimethoxyphenyl)ethyl]-1,3,4-thiadiazol-2-yl}-3-m-tolylurea,

1-(3-chloro-4-methylphenyl)-3-[5-(2-methyl-1-phenylpropyl)-1,3,4-thiadiazol-2-yl]urea,

1-(3-chlorophenyl)-3-[5-(3,4-dimethoxyphenoxy)-1,3,4-thiadiazol-2-yl]urea,

1-(3-chlorophenyl)-3-[5-(3,4-dimethoxybenzoyl)-1,3,4-thiadiazol-2-yl]urea,

1-(3-chlorophenyl)-3-{5-[2-(3,4-dimethoxyphenyl)ethyl]-1,3,4-thiadiazol-2-yl}urea,

1-(5-chloro-2,4-dimethoxyphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-(3-chlorophenyl)-3-[5-(3,4-dimethoxybenzylamino)-1,3,4-thiadiazol-2-yl]-urea,

1-[5-(3,4-dimethoxyphenylamino)-1,3,4-thiadiazol-2-yl]-3-(3-tri-fluoromethylphenyl)urea,

1-[5-(3,4-dimethoxyphenoxy)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoro-

methylphenyl)urea,

1-[5-(4-chlorophenoxymethyl)-1,3,4-thiadiazol-2-yl]-3-(4-fluoro-3-trifluoromethylphenyl)urea,

1-(5-chloro-2-methoxyphenyl)-3-{5-[2-(3,4-dimethoxyphenyl)ethyl]-1,3,4-thiadiazol-2-yl}urea,

1-(5-chloro-2-methoxyphenyl)-3-[5-(3,4-dimethoxybenzoyl)-1,3,4-thiadiazol-2-yl]urea,

1-(5-chloro-2-methoxyphenyl)-3-[5-(3,4-dimethoxybenzylamino)-1,3,4-thiadiazol-2-yl]urea,

1-{5-[2-(3,4-dimethoxyphenyl)ethyl]-1,3,4-thiadiazol-2-yl}-3-(3-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxybenzylamino)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxyphenylamino)-1,3,4-thiadiazol-2-yl]-3-(2-fluoro-3-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxyphenoxy)-1,3,4-thiadiazol-2-yl]-3-(2-fluoro-3-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxyphenoxy)-1,3,4-thiadiazol-2-yl]-3-(4-fluoro-3-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxybenzoyl)-1,3,4-thiadiazol-2-yl]-3-(3-fluoro-5-trifluoromethylphenyl)urea,

1-{5-[2-(3,4-dimethoxyphenyl)ethyl]-1,3,4-thiadiazol-2-yl}-3-(3-fluoro-5-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxybenzoyl)-1,3,4-thiadiazol-2-yl]-3-(2-fluoro-5-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxybenzoyl)-1,3,4-thiadiazol-2-yl]-3-(4-fluoro-3-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxybenzoyl)-1,3,4-thiadiazol-2-yl]-3-(2-fluoro-3-trifluoromethylphenyl)urea,

1-{5-[2-(3,4-dimethoxyphenyl)ethyl]-1,3,4-thiadiazol-2-yl}-3-(4-fluoro-3-trifluoromethylphenyl)urea,

1-{5-[2-(3,4-dimethoxyphenyl)ethyl]-1,3,4-thiadiazol-2-yl}-3-(2-fluoro-3-trifluoromethylphenyl)urea,

1-{5-[2-(3,4-dimethoxyphenyl)ethyl]-1,3,4-thiadiazol-2-yl}-3-(2-fluoro-5-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxybenzylamino)-1,3,4-thiadiazol-2-yl]-3-(2-fluoro-3-trifluoromethylphenyl)urea,

1-(4-chloro-3-trifluoromethylphenyl)-3-{5-[2-(3,4-dimethoxyphenyl)ethyl]-1,3,4-thiadiazol-2-yl}urea,

1-(4-chloro-3-trifluoromethylphenyl)-3-[5-(3,4-dimethoxybenzoyl)-1,3,4-thiadiazol-2-yl]urea,

1-(4-chloro-3-trifluoromethylphenyl)-3-[5-(3,4-dimethoxybenzylamino)-1,3,4-thiadiazol-2-yl]urea,

1-(3,5-bistrifluoromethylphenyl)-3-[5-(3,4-dimethoxyphenylamino)-1,3,4-thiadiazol-2-yl]urea,

1-(3,5-bistrifluoromethylphenyl)-3-[5-(3,4-dimethoxybenzoyl)-1,3,4-thiadiazol-2-yl]urea,

1-(3,5-bistrifluoromethylphenyl)-3-{5-[2-(3,4-dimethoxyphenyl)ethyl]-1,3,4-thiadiazol-2-yl}urea,

1-(3,5-bistrifluoromethylphenyl)-3-[5-(3,4-dimethoxybenzylamino)-1,3,4-thiadiazol-2-yl]urea,

1-(3-chlorophenyl)-3-[5-(pyridin-4-yloxy)-1,3,4-thiadiazol-2-yl]urea,

1-[5-(pyridin-4-yloxy)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoromethylphenyl)-urea,

1-(4-fluoro-3-trifluoromethylphenyl)-3-[5-(pyridin-4-yloxy)-1,3,4-thiadiazol-2-yl]urea,

1-(2-fluoro-3-trifluoromethylphenyl)-3-[5-(pyridin-4-yloxy)-1,3,4-thiadiazol-2-yl]urea,

1-(2-fluoro-5-trifluoromethylphenyl)-3-[5-(pyridin-4-yloxy)-1,3,4-thiadiazol-2-yl]urea,

1-(3,5-bistrifluoromethylphenyl)-3-[5-(pyridin-4-yloxy)-1,3,4-thiadiazol-2-yl]urea,

1-(5-chloro-2-methoxyphenyl)-3-[5-(4-chlorophenoxymethyl)-1,3,4-thiadiazol-2-yl]urea,

1-[5-(4-chlorophenoxymethyl)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoro-methylphenyl)urea,

1-[5-(3,4-dimethoxybenzoyl)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoro-methylphenyl)- urea,

1-[5-(3,4-dimethoxyphenoxymethyl)-1,3,4-thiadiazol-2-yl]-3-m-tolylurea,

1-(3-chlorophenyl)-3-[5-(3,4-dimethoxyphenoxymethyl)-1,3,4-thiadiazol-2-yl]urea,

1-(5-chloro-2-methoxyphenyl)-3-[5-(3,4-dimethoxyphenoxymethyl)-1,3,4-thiadiazol-2-yl]urea,

1-[5-(3,4-dimethoxyphenoxymethyl)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxyphenoxymethyl)-1,3,4-thiadiazol-2-yl]-3-(2-fluoro-3-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxyphenoxymethyl)-1,3,4-thiadiazol-2-yl]-3-(3-fluoro-5-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxyphenoxymethyl)-1,3,4-thiadiazol-2-yl]-3-(4-fluoro-3-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxyphenoxymethyl)-1,3,4-thiadiazol-2-yl]-3-(2-fluoro-5-trifluoromethylphenyl)urea,

1-(4-chloro-3-trifluoromethylphenyl)-3-[5-(3,4-dimethoxyphenoxymethyl)-1,3,4-thiadiazol-2-yl]urea,

1-(3,5-bistrifluoromethylphenyl)-3-[5-(3,4-dimethoxyphenoxymethyl)-1,3,4-thiadiazol-2-yl]urea,

(S)-1-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoromethylphenyl)-urea,

(R)-1-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoromethylphenyl)-urea,

(S)-1-(5-chloro-2-methoxyphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea enantiomer,

(R)-1-(5-chloro-2-methoxyphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

(S)-1-(4-fluoro-3-trifluoromethylphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

(R)-1-(4-fluoro-3-trifluoromethylphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea

~~and~~or pharmaceutically usable ~~derivatives,~~ solvates, salts ~~and~~or stereoisomers thereof, including mixtures thereof in all ratios.

13. (Currently Amended) ~~Process~~A process for the preparation of ~~the~~ compounds according to Claim 11 ~~and~~or pharmaceutically usable ~~derivatives,~~ salts, solvates ~~and~~or stereoisomers thereof, ~~characterised in that~~comprising reacting

a) a compound of ~~the~~ formula II



II

,

in which ~~Y, Z and Ar^2 each have the same meaning as in the compound according to Claim 11 to be prepared.~~

~~and~~ L denotes Cl, Br, I or a free or reactively functionally modified OH group,

~~is reacted~~ with a compound of ~~the~~ formula III

$$Ar^1\text{-}NH_2 \qquad \text{III},$$

~~in which Ar^1 has the same meaning as in the compound according to Claim 11 to be prepared,~~

or

b) reacting a compound of ~~the~~ formula IV



IV

~~in which Ar^1 has the same meaning as in the compound according to Claim 11 to be prepared,~~

~~is reacted~~ with a compound of ~~the~~ formula V



V

~~in which Z and Ar^2 each have the same meaning as in the compound according to Claim 11 to be prepared,~~

and/or

converting a base or acid of ~~the~~ formula I ~~is converted~~ into one of its salts.

14. (Currently Amended) ~~Medicament~~A pharmaceutical composition comprising at least one compound according to Claim 11 and/or one of its pharmaceutically usable ~~derivatives, s~~alts, solvates ~~and~~or stereoisomers, including mixtures thereof in all ratios, and ~~optionally excipients and/or adjuvants~~a pharmaceutically acceptable carrier.

15. (Currently Amended) ~~Set (kit)~~A kit consisting of separate packs of

a) an effective amount of a compound of the formula I and/or pharmaceutically usable ~~derivatives~~, solvates ~~and~~or stereoisomers thereof, including mixtures thereof in all ratios,
and

b) an effective amount of a further medicament active ingredient.